Skip to main content

Table 2 Treatment utilization among esSCLC and mNSCLC patients, by tumor type

From: Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers

 

Study groups

P value

esSCLC

mNSCLC

(N = 5,855)

(N = 24,090)

Post-index prevalence of cancer-directed therapies

   

 Overall, n (%)a

   

  Surgery

458 (7.8)

3,278 (13.6)

< 0.001

  Radiation therapy

3,827 (65.4)

18,208 (75.6)

< 0.001

  Biologic therapy

103 (1.8)

282 (1.2)

< 0.001

  Chemotherapy

5,003 (85.4)

14,527 (60.3)

< 0.001

    No. cycles received in first-line treatment, mean (SD)

3.4 (2.1)

3.2 (2.3)

 

Post-index prevalence of supportive or palliative therapies

   

 Growth factors, n (%)a

   

  Filgrastim/pegfilgrastim/sargramostim

2,483 (42.4)

4,275 (17.8)

< 0.001

  Darbepoetin/erythropoietin

2,926 (50.0)

8,640 (35.9)

< 0.001

  Any growth factor

3,453 (59.0)

9,506 (39.5)

< 0.001

 Other supportive or palliative therapies, n (%)a

   

  Iron supplements

39 (0.7)

249 (1.0)

0.012

  Antibiotics

613 (10.5)

2,328 (9.7)

0.063

  Antiemetics

4,095 (69.9)

12,947 (53.7)

< 0.001

  Antifungalsb

 

21 (0.1)

 

  Pain medications

1,366 (23.3)

5,782 (24.0)

0.280

  Bisphosphonates

373 (6.4)

2,271 (9.4)

< 0.001

  Megestrol acetate

2,276 (38.9)

6,078 (25.2)

< 0.001

  Oxygen

1,696 (29.0)

6,861 (28.5)

0.118

  Red blood-cell transfusion

1,212 (20.7)

2,629 (10.9)

< 0.001

  Platelet transfusion

330 (5.6)

426 (1.8)

< 0.001

  1. mNSCLC = non-small cell lung cancer; esSCLC = small cell lung cancer.
  2. aCategories are not mutually exclusive.
  3. bPer National Cancer Institute protocol, data suppressed due to cell size <11.